Literature DB >> 16750503

Temozolomide: a novel treatment for pituitary carcinoma.

Stephen Lim1, Hrayr Shahinian, Menahem M Maya, William Yong, Anthony P Heaney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16750503     DOI： 10.1016/S1470-2045(06)70728-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  52 in total

Review 1.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 2.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

3.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

4.  Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.

Authors:  Genya Aharon-Hananel; Ruth Percik; Muhamad Badarna; Inbal Uri; Amit Tirosh
Journal:  Endocrine       Date:  2019-07-02       Impact factor: 3.633

5.  Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

Authors:  Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

Review 6.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 7.  Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

Authors:  Frederick Yoo; Edward C Kuan; Anthony P Heaney; Marvin Bergsneider; Marilene B Wang
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 8.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

9.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

10.  Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.

Authors:  Marie S Thearle; Pamela U Freda; Jeffrey N Bruce; Steven R Isaacson; Yoomi Lee; Robert L Fine
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.